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Abstract
Inflammation is an important environmental factor that promotes tumourigenesis and the progression of established 
cancerous lesions, and recent studies have started to dissect the mechanisms linking the two pathologies. These 
inflammatory and infectious conditions trigger immune and stromal cell release of soluble mediators which facilitate 
survival and proliferation of tumour cells in a paracrine manner. In addition, (epi-)genetic mutations affecting 
oncogenes, tumour-suppressor genes, chromosomal rearrangements and amplifications trigger the release of 
inflammatory mediators within the tumour microenvironment to promote neoplastic growth in an autocrine manner. 
These two pathways converge in tumour cells and result in activation of the latent signal transducer and activator of 
transcription 3 (Stat3) which mediates a transcriptional response favouring survival, proliferation and angiogenesis. The 
abundance of cytokines that activate Stat3 within the tumour microenvironment, which comprises of members of the 
interleukin (IL) IL6, IL10 and IL17/23 families, underpins a signaling network that simultaneously promotes the growth 
of neoplastic epithelium, fuels inflammation and suppresses the host's anti-tumour immune response. Accordingly, 
aberrant and persistent Stat3 activation is a frequent observation in human cancers of epithelial origin and is often 
associated with poor outcome.
Here we summarize insights gained from mice harbouring mutations in components of the Stat3 signaling cascade 
and in particular of gp130, the shared receptor for the IL6 family of cytokines. We focus on the various feed-back and 
feed-forward loops in which Stat3 provides the signaling node in cells of the tumour and its microenvironment thereby 
functionally linking excessive inflammation to neoplastic growth. Although these observations are particularly 
pertinent to gastrointestinal tumours, we suggest that the tumour's addiction to persistent Stat3 activation is likely to 
also impact on other epithelial cell-derived cancers. These insights provide clues to the judicious interference of the 
gp130/Stat3 signaling cascade in therapeutically targeting cancer.
Introduction
Chronic infection and the ensuing inflammation are
among the most important epigenetic and environmental
factors that contribute to tumourigenesis and the pro-
gression of established cancerous lesions [1]. Aberrant
proliferation alone is insufficient to cause cancer, which
requires both an initial mutagenizing event that triggers
neoplastic behaviour, as well as a microenvironment that
is rich in factors which support cellular survival, growth
and promote angiogenesis. Many of these cytokines,
angiogenic factors and chemokines are produced by acti-
vated stroma and immune cells which accumulate in situ
during chronic inflammation [1]. As these factors not
only exert profound effects on (neoplastic) epithelium,
endothelial and mesenchymal cells, but also recruit
immune cells, the cancer microenvironment shares many
molecular features of a 'never healing wound'. In addition,
tumour cells themselves acquire the ability to subvert the
host's anti-tumourigenic innate and adaptive immune
responses [2,3]. Accordingly, the risk of cancer develop-
ment increases with the failure to appropriately resolve
immune responses, which promote excessive tissue
remodeling, loss of tissue architecture, and cellular stress
on proteins and DNA.
Compelling evidence for a link between inflammation
and cancer comes from several epidemiological studies.
Chronic inflammation triggered by viral or bacterial
infection increases the risk for the development of papil-
loma virus-associated cervical cancer [4,5], hepatitis B
and C-associated hepatocellular carcinoma and Epstein
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Barr virus-associated lymphoproliferative disorder [6],
and bacterial infections can promote metastasis following
surgery [7]. In the gastrointestinal tract, Helicobacter
pylori (H.pylori)-associated gastric cancer along with
ulcerative colitis and Crohn's disease-associated colorec-
tal cancer comprise major health issues. Besides familial
adenomatous polyposis and the hereditary nonpolyposis
colon cancer syndrome, ulcerative colitis accounts for
one of the three highest risk groups for developing col-
orectal cancer [8,9]. Accordingly, the use of non-steroidal
anti-inflammatory drugs (NSAIDs) and inhibitors of the
rate limiting Cox-2 enzyme in the prostaglandin E2 path-
way, not only inhibits chronic inflammation in patients
with premalignant disease, but also reduces the risk of
cancer of the colon, lung, stomach, esophagus and ovaries
[10].
In recent years, studies in genetically modified mice
have helped to dissect and characterize some of the
underlying molecular events that link inflammation to
cancer [11,12]. For instance, the development of colorec-
tal cancer is increased in various knockout mouse models
of inflammatory bowel disease [13-16], and epidemiolog-
ical evidence links polymorphisms in the corresponding
genes to increased inflammation and cancer susceptibil-
ity in humans. Perhaps the greatest insights, however,
have been mutant mice carrying loss- and gain-of-func-
tion mutations in intracellular components where a num-
ber of oncogenic signalling cascades converge. In this
review we focus on Stat3, because it provides a central
signaling node for neoplastic cells to induce transcrip-
tional responses which promote tumour growth. Stat3 is
aberrantly activated in a majority of cancers of epithelial
origin [17,18]. Moreover, Stat3 plays an important role in
determining the outcome of the interaction between can-
cers and immune cells, both in terms of suppressing anti-
tumour activities as well as facilitating a tumour promot-
ing inflammatory microenvironment. These roles have
recently been clarified in the gastrointestinal tract, where
Stat3 has attracted attention for its capacity to function-
ally link inflammation to tumourigenesis (Figure 1).
Stat3 mode of action
All seven Stat proteins act as latent transcription factors
that primarily mediate signalling from cytokine and
growth factor receptors. Following their activation
through phosphorylation on carboxy-terminally located
conserved tyrosine residues and subsequent reciprocal
SH2 domain interaction, Stat proteins form stable homo-
and/or heterodimers in the cytoplasm [15]. Their subse-
quent nuclear translocation enables binding to DNA in a
sequence-specific manner and results, usually in con-
junction with other cofactors, in transcriptional regula-
tion of target genes. Different Stat proteins show
preferred specificity for individual cytokine family recep-
tors. Stat1 primarily promotes growth arrest, apoptosis,
and anti-tumour immunity downstream of type I and II
interferons as demonstrated by the susceptibility of Stat1-
deficient mice to develop tumours [19]. By contrast, Stat3
mediates activity of cytokines generally associated with
systemic acute phase and cancer-promoting inflamma-
tory responses. Stat3 can also be activated by other can-
cer-associated receptor tyrosine kinases, including those
for epidermal growth factor and scatter factor c-Met [20-
22]. Meanwhile, cellular transformation by the cytoplas-
mic tyrosine kinase c-src [23] or chromosomal transloca-
tion involving the anaplastic lymphoma kinase Alk is also
dependent on Stat3 [24,25]. These cytoplasmic tyrosine
kinases, often in conjunction with Jaks, are likely to medi-
ate Stat3 activation subsequent to many other cancer-ini-
tiating, toxic insults, including UV-radiation, stress, and
smoke [26,27].
Functionally the most important Stat3 regulators are
the IL6 and IL10 family of cytokines (Figure 2). The IL6
family of ligands is defined by its shared use of the gp130
receptor β-subunit. Binding of IL6 and IL11 to their
respective IL6Rα and IL11Rα receptor subunits triggers
gp130 homodimerisation, while the remaining IL-6 fam-
ily ligands (comprising LIF, CNTF, CT-1, Oncostatin M
and IL27) induce formation of heterodimeric gp130
receptor complexes [16]. Engagement of gp130 triggers
activation of the associated Janus kinases Jak1, Jak2 and
Tyk2 [28,29] and subsequent tyrosine phosphorylation of
gp130. While the four membrane-distal residues in the
cytoplasmic tail of gp130 are required and sufficient for
subsequent activation of Stat3, and to a lesser extent of
Stat1, an additional membrane-proximal phospho-
tyrosine residue (Y757 in mouse, Y759 in human) enables
activation of the Ras/ERK pathway via the tyrosine phos-
Figure 1 Hematopoietic cell infiltration and STAT3 hyperactiva-
tion in gastrointestinal tumours. (A) Haematopoietic cell infiltration 
(green) in gastric tumours of gp130Y757F mutant mice visualized follow-
ing adoptive transfer of bone marrow from GFP-transgenic mice. 
Metaplastic gastric epithelium is visualized following antibody binding 
to the intestine-specific epithelial cells surface marker gpA33 (red) 
[164]. (B) Immunohistological stain for activated STAT3 in sections of 
spontaneous arising gastric and CAC-induced colonic adenomas in 
gp130Y757F mutant mice, and from human gastric and colonic adeno-
carcinomas using an antibody directed against tyrosine phosphorylat-
ed STAT3.
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phatase Shp-2. The same phospho-tyrosine in gp130 also
serves as the binding site for the negative regulator Socs3,
which is transcriptionally induced by Stat3. Binding of
Socs3 to the activated gp130 complex results in its prote-
osomal degradation, thereby maintaining Stat3 activity of
a transient nature. Accordingly, tissue-specific Socs3
ablation in mice amplifies ligand-dependent gp130 sig-
nalling, while the Y757F tyrosine-to-phenylalanine substi-
tution in the corresponding gp130Y757F knock-in mutant
mice results in excessive activation of Stat3 and Stat1
[30,31]. Interestingly, in the context of gp130 mediated
Stat activation, Stat1 and Stat3 are capable of regulating
each other [32,33].
The IL10 family of cytokines shares the common
IL10Rβ receptor subunit and comprises IL10, IL19, IL22
and IL24. IL10 confers broad anti-inflammatory
Figure 2 Regulation of intracellular Stat3 signalling. Stat3 signalling is induced by various kinases (green) in a phosphorylation dependent man-
ner (green arrows), and counteracted by several regulatory proteins (red). For instance, Stat3 activation occurs in response to gp130 homodimeriza-
tion following binding of IL6 or IL11 (blue) to their specific transmembrane receptor α-subunits (white) [165]. Phosphorylation of four membrane distal 
tyrosine (Y, black) residues by constitutively associated JAK-family tyrosine kinases (TK) is sufficient to enable src-homology domain (SH)-2 mediated 
binding of STAT3 and, to a lesser extent, of STAT1. Once tyrosine phosphorylated, STAT1/3 form homo- and heterodimers, which translocate and trans-
activate target genes, including the negative regulator SOCS3. STAT3 can also be phosphorylated by certain cytosolic TKs and receptor TK. Meanwhile, 
serine threonine kinases (STK) mediate serine-phosphorylation that maximizes the transcriptional activity of STAT3 and enables its mitochondrial tar-
geting. Gp130 also engages the Ras/ERK pathway through binding of the tyrosine phosphatase SHP2 to the membrane proximal phospho-YxxV con-
sensus sequence (red, where V is valine and × any amino acid). This phosphor-tyrosine also provides the binding site for SOCS3 to mediate 
proteasomal degradation of ligand-occupied receptor complexes. Gp130 signaling is also attenuated by the Y-phosphatase activity of SHP2, while 
cytoplasmic PIAS3 protein sequesters Y-phosphorylated STAT3 from homodimerization, nuclear translocation and target gene activation. Represen-
tative examples of different types of bona-fide Stat3 target genes are listed [166].Jarnicki et al. Cell Division 2010, 5:14
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responses in IL10Rα chain expressing cells, and these
responses are amplified in a feed-forward loop encom-
passing Stat3-dependent transcriptional induction of Il10
[34]. Accordingly, mice lacking il10 or harbouring Stat3-
deficient macrophages are characterized by excessive
cytokine release and develop colitis [35,36]. IL22 is
expressed during chronic inflammation by Th17, natural
killer (NK) and Dendritic (DC) cells [37] and acts on IL-
22R subunit expressing (intestinal) epithelial cells to
induce IL10 and acute phase protein production [38].
Since the IL10-family receptor subunits lack Socs3 bind-
ing sites, IL10-mediated receptor engagement results in
sustained Stat3 activation (Figure 3). Thus at least in
macrophages, Socs3 provides the key molecular switch
determining whether Stat3 promotes an inflammatory or
anti-inflammatory response [39]. Accordingly, transient
Stat3 activation by IL6 in wild-type macrophages pro-
motes an inflammatory response, while sustained Stat3
activation by IL6 of gp130Y757F mutant macrophages sup-
presses the inflammatory gene response through the
induction of transcriptional repressors [39,40]. Similarly,
sustained gp130 and Stat3 activation in Socs3-deficient
macrophages triggers a strong anti-inflammatory
response [41-43] and expression of the canonical TGFβ
signaling pathway inhibitor Smad7 [31].
Since Stat3 occupies a central node for many converg-
ing signaling pathways, excessive Stat3 activity in
tumours can result from oversupply of (IL6-family)
cytokines and other growth factors within the tumour
microenvironment. Besides these paracrine (or cell-
extrinsic) pathways, activation of (proto-)oncogenes,
inactivation of tumour-suppressor genes, chromosomal
rearrangement/amplification and other genetic events in
neoplastic cells either directly trigger Stat3 activation, or
the release of inflammatory mediators as part of an auto-
crine (or cell-intrinsic) pathway. Remarkably, there is no
genetic evidence for constitutively activating mutations
within STAT3 itself. However, a variety of cancers har-
bour activating point mutations in Jak2 [44] and gp130
in-frame deletion mutations, which mediate ligand-inde-
pendent activation of Stat3, are found in hepatocellular
carcinomas [45]. Excessive activation of Stat3 can also
result from impairment mutations affecting any of the
negative regulatory proteins which limit the extent of
Stat3 activation under physiological conditions [46]. For
instance, epigenetic silencing of the negative regulator
SOCS3 occurs in epithelial cancers [47], while other can-
cers show somatic mutations in Stat3-inactivating phos-
phatases T and δ [48,49]. Owing to their capacity to
inactivate upstream tyrosine kinases or to sequester
phosphorylated Stat3 from de novo Stat-dimers, muta-
genic alterations in the cytosolic tyrosine phosphatases
CD45 [50,51], SHP1 and SHP2 [50,51], or the SUMO E3
ligase Pias3 [52] and Grim19 [53] are also expected to
result in excessive activation of Stat3-dependent target
genes.
Cellular outcomes of Stat3 activation
A decade ago, Hanahan and Weinberg have suggested
that the malignant growth characteristics of cancer cells
requires six essential alterations in cellular physiology,
namely self-sufficiency in growth signals, insensitivity to
growth inhibiting signals, evasion of apoptosis, unlimited
cellular replication, sustained angiogenesis, and tissue
invasion and metastasis [54]. They argued that each
change represents a new capability acquired during
tumour development which overcomes rate limiting steps
for anti-cancer defence mechanisms in normal cells. Stat3
promotes at least three of these hallmarks (proliferation,
survival and angiogenesis) and often more when investi-
gated in specific cell types.
Stat3 inhibits apoptosis by up-regulating the pro-sur-
vival Bcl-2 proteins Bcl-XL, Mcl-1 and Bcl-w [55-58]. In
epithelial cells, Stat3 also induces other proteins that
indirectly suppress apoptosis, including the chaperone
protein Hsp70 [59] and the C-type lectin-type RegIIIβ,
which are both overexpressed in human colon cancer and
inflammatory bowel disease [60,61] (Figure 2). In con-
junction with c-jun, Stat3 inhibits the extrinsic apoptosis
pathways through transcriptional repression of the FAS
death receptor [62]. Stat3-mediated induction of survivin
not only suppresses apoptosis, but also promotes mito-
genic progression through binding to cdc2 [63,64]. How-
ever, Stat3 promotes proliferation primarily by
stimulating transcription of cyclinB1,  cdc2,  c-myc  and
cyclinD1  [55,65,66], along with the induction of the
immediate early genes c-jun and c-fos [67] and repression
of the cell cycle inhibitor p21 [68]. Accordingly, Stat3 pro-
motes the G1/S phase transition of the cell cycle in gas-
tric, colon and squamous cell carcinoma, as well as in
bladder cancer cells [65,68-70]. By contrast, Stat3 abla-
tion in intestinal epithelium in vivo or in tumour cell lines
in vitro resulted in cell cycle arrest in the G2/M transition
and is associated with histone H3 phosphorylation-asso-
ciated mitotic arrest [68].
Among the angiogenic factors, VEGF and HIF1α stand
out as prominent transcriptional targets for Stat3 [71,72],
and a requirement for Stat3 has been proposed for func-
tionality of HIF1α [73]. Accordingly, Stat3 is required for
endothelial cell survival and their arrangement into new
vascular structures [74], while nuclear Stat3 correlates
with enhanced VEGF expression and microvessel density
in gastric cancer [75,76]. Since Stat3 inhibition also
blocks VEGF expression in tumours characterized by
aberrant activation of Src [77], therapeutic targeting of
Stat3 may inhibit neovascularisation in tumours associ-
ated with excessive signaling through epidermal growth
factor receptor. Stat3 may also promote neovascularisa-Jarnicki et al. Cell Division 2010, 5:14
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tion by mediating endothelial cell responses to other
growth factors, including granulocyte-macrophage stim-
ulating factor [78]. Excessive activation of Stat3 correlates
with tumour invasion and metastasis in a variety of can-
cers [17,18] and high level of tyrosine-phosphorylated
STAT3 is a pertinent feature in colon and gastric cancers
Figure 3 Strength and duration of STAT3 activation determines cellular responses. STAT3 activation patterns and associated outcomes differ 
between IL6 and IL10 family cytokine-induced signaling. In response to binding of ligand (blue), signaling from gp130 is transient, because the phos-
phorylated, membrane proximal tyrosine residue (Y, red) provides a binding site for the negative regulator SOCS3. Although SOCS3 is also induced in 
response to activation of the IL10 receptor family, STAT3 signaling remains sustained, because the IL10 receptor chains lack the corresponding YxxV 
motif. Similarly, signaling from the mutant gp130Y757F receptor is sustained due to phenylalanine (F) substitution of the Y757 residue (Y759 in human 
GP130), resulting in exaggerated activation of its down-stream signaling molecules. The range of target genes activated differs between acute and 
sustained STAT3 activation, most evident in macrophages where the former promotes and the latter suppresses inflammatory response.Jarnicki et al. Cell Division 2010, 5:14
http://www.celldiv.com/content/5/1/14
Page 6 of 15
associated with adverse outcomes [79] (Figure 1). Finally,
Stat3 is part of the transcriptional network that mediates
epithelial-to-mesenchymal (EMT) transformation in
glioblastoma [80] and promotes metastasis by induction
of the extracellular matrix-degrading metalloproteinases,
including MMP-2 and MMP-9 [81].
Experimental carcinogenesis
To understand the function of Stat3 during carcinogene-
sis, it is helpful to divide (experimental) carcinogenesis
into three distinct stages with an irreversible, genetic
alteration providing the tumour initiating event. Subse-
quent tumour promotion occurs as a consequence of
expansion of these genetically altered, pre-neoplastic cells
which is frequently associated with an inflammatory
response within the tumour microenvironment. Further
tumour progression and growth coincides with the acqui-
sition of additional (epi-)genetic changes, which ulti-
mately enable the primary tumour to spread to distant
metastatic sites. These sequential carcinogenesis pro-
cesses can be experimentally recapitulated in mice using
two-hit models employing 7,12-dimethylbenz(a) anthra-
cene (DMBA) and 12-O-tetradecanoylphorbo-13-ace-
tate (TPA) in the skin [82], or the azoxymethane (AOM)
plus the polysaccharide dextran sodium sulfate (DSS) in
the colitis-associated cancer (CAC) model of the colon
[68]. In a hepatocellular carcinoma model, a two stage
strategy is used by injecting diethylenitrosamine (DEN)
as the tumour initiator and phenobarbitol as the pro-
moter [83].
Stat3 in epithelial cancer cells
In the CAC model, inflammation triggered through pro-
longed administration of DSS reveals the mutagenic
effect of prior exposure to the colonotropic mutagen
AOM. DSS-mediated epithelial damage and impairment
o f  e p i t h e l i a l  b a r r i e r  f u n c t i o n  e n a b l e s  c o m m e n s a l
microbes to activate resident macrophages and release
inflammatory cytokines, such as IL1, TNFα and IL6. In
the absence of epithelial Stat3 expression, this results in
the formation of occasional low-grade intraepithelial
neoplastic lesions, while epithelial Stat3 proficiency
enables progression of these lesions into advanced tubu-
lar tumors [68,84]. Conversely, excessive Stat3 activation,
through epithelial-specific Socs3 ablation or introduction
of the Socs3-binding deficient gp130Y757F  mutation,
results in increased tumour burden both in terms of
tumour size as well as incidence [68,85]. Similar findings
were obtained in the skin, where keratinocyte-specific
Stat3 ablation abrogated skin tumour development [86],
while keratinocyte-specific expression of the artificial,
transcriptionally constitutive active Stat3C mutant, pro-
moted the formation of squamous cell carcinoma in situ
[82]. In either situation, Stat3 suppressed apoptosis of
(mutagenized) stem and progenitor cells in the bulge
region of the skin or the intestinal crypt, thereby curbing
either their chance to be mutated or to subsequently
expand [86] (Phesse T, Buchert M, Ernst M: Epistatic
interaction between aberrant Wnt and Stat3 signaling
during intestinal tumorigenesis, submitted). Consistent
with these observations, systemic ablation of the il6 gene
conferred a partial protective effect against tumour pro-
motion in the CAC model, since IL6 enhances survival,
proliferation and possibly cellular migration of entero-
cytes and their transformed counterparts that originated
from the intestinal stem or transiently amplifying cell
compartments [87,88]. Excessive abundance of IL6 also
exacerbates colitis by suppressing apoptosis of infiltrating
T-cells through "trans-signaling", whereby shedding of
the extracellular domain from IL6Rα-proficient epithe-
lium provides a soluble, ligand-binding receptor subunit
for IL6 to activate gp130 in IL6Rα-deficient T-cells [89].
Thus, administration of either neutralizing IL6Rα anti-
bodies or soluble gp130Fc suppressed enterocyte-specific
Stat3 activation and proliferation, and reduced tumor
incidence [90]. Concomitant overexpression of IL6 and
IL6Rα in double transgenic mice is sufficient to induce
hepatocellular carcinomas [91] and administration of
Hyper-IL6, but not IL6, increased colonic tumours in
CAC-challenged wild-type mice [84]. Due to the capacity
of Hyper-IL6, a fusion protein between IL6 and IL6Rα
[87,88], to activate gp130 receptors independently of the
presence of the ligand-binding IL6Rα subunit, these
observations suggest that cancer-initiating cells may not
always express sufficient IL6Rα subunits to respond to
IL6. In genetic complementation studies, we found func-
tional redundancy between the IL6 and IL11 signaling in
intestinal epithelium, where both cytokines were equally
potent in conferring Stat3-dependent, epithelial resis-
tance to DSS-induced apoptosis and colitis [68]. Consis-
tent with these observations, IL11 administration
protected against radiation-induced mucositis, suggest-
ing that IL11 signaling may play an important role in the
maintenance of intestinal epithelium [92]. Genetic defi-
ciency for the ligand binding IL-11Rα subunit completely
abrogates gastric tumour formation in gp130Y757F mice,
and mono-allelic il11ra ablation delayed the onset and
reduced overall gastric tumour burden [32]. However,
unlike the observations in the colon, gastric tumourigen-
esis in gp130Y757F mice occurred independently of IL6
[32]. Meanwhile, systemic reduction of Stat3 expression
in  gp130Y757F;Stat3+/-  mice not only prevented gastric
tumour formation [31], but also reduced their suscepti-
bility to colonic tumourigenesis in the CAC model [93].
Surprisingly,  Stat1  gene inactivation also partially
reduces gastric tumourigenesis in gp130Y757F mice [32],
despite its general function in mediating IFNγ-dependent
anti-tumour immunity [19]. However, therapeutic appli-Jarnicki et al. Cell Division 2010, 5:14
http://www.celldiv.com/content/5/1/14
Page 7 of 15
cation of Stat3-antisense oligonucleotides or IL11 antago-
nists to gp130Y757F  mice, suggest that growth and
maintenance of gastric tumours remains dependent on
the continuous activation of Stat3 [31,93].
Is excessive Stat3 activation in epithelial cells sufficient
to trigger de novo tumour formation? In models akin to
(onco-)gene amplification, enforced transgenic expres-
sion of constitutive active STAT3C confers tumourigenic
capacity in a 3T3 xenograph model. Overexpression of
STAT3C in vivo also induced broncho-alveolar adenocar-
cinomas [94] and the formation of squamous cell carci-
noma in situ [82] when expressed in alveolar II epithelial
cells or keratinocytes, respectively. Significantly, bron-
choalveolar adenocarcinomas in STAT3C transgenic
mice were preceded by inflammatory cell infiltrates and
tumour development was associated with excessive
secretion of inflammatory cytokines, including IL6 [94].
Even though there is no evidence for tumour-specific
amplification of the STAT3  locus in humans, excessive
activation of endogenous Stat3 reproducibly promotes
gastric adenoma formation in gp130Y757F mice at a very
young age. T umour initiation and growth in this model
correlates with bacterial load, because prophylactic anti-
microbial treatment delayed the occurrence of these
tumours [95]. Surprisingly, tumour development in
gp130Y757F mice is restricted to the glandular stomach
despite systemic hyperactivation of endogenous Stat3.
Consistent with this finding, we also observed that
enforced, ligand-independent activation of endogenous
Stat3 in the epithelium of the small and large intestine
failed to confer tumour development in transgenic mice
[96]. Since the gp130Y757F germline mutation also impairs
Figure 4 Stat3 links inflammation to cancer. Inflammation and cancer are functionally linked by intrinsic, Stat3-dependent autocrine feedback 
loops in neoplastic epithelium (red arrows) and extrinsic, feedforward and often reciprocal interactions between tumour, inflammatory and stromal 
cells that collectively make up the microenvironment (green arrows) [167]. The ubiquitous expression of gp130 and the capacity of STAT3 to stimulate 
its own transcription as well as that of gp130 ligands (in particular IL6 and IL11) also provides numerous amplification loops between the different cell 
types. Furthermore, limited responsiveness to IL6 and IL11 imposed by restricted expression of the ligand-specific receptor α-subunits can be over-
come by IL6-transsignaling [90]. Excessive cell-intrinsic STAT3 activation is also triggered by oncogenic events from (epi-)genetic activation of positive 
regulators (i.e. receptor (-associated) TKs) and loss of function mutations of negative regulators (i.e. SOCS3). Expression of IL6 is also directly induced 
by NF-κB and indirectly through a feedback mechanism including lin28 and the let7-microRNA, while latent Stat3 in conjunction with NF-κB triggers 
non-canonical IL6 expression. Epithelial NF-κB and STAT3 are activated in response to the abundantly present inflammatory cytokines IL1, TNFα and 
IL6 which are released from TLR-activated myeloid cell (macrophages), with IL6 and IL11 also contributed by tumour-associated stromal fibroblast and 
myoepithelial cells. Meanwhile, release of IL17 and IL22 from mature Th17 cells provide an additional extrinsic link which results in excessive STAT3 
activation in tumour cells.Jarnicki et al. Cell Division 2010, 5:14
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expression of the stomach-specific tumour suppressor
gene tff1 [30], and since all colonic tumours in CAC-chal-
lenged gp130Y757F mice harbour mutagen-induced onco-
genic conversions of β-catenin, excessive activation of
endogenous Stat3 may only promote tumour growth in
conjunction with preexisting tumour-initiating muta-
tion(s). However, these observations may also predicate
the (co-)existence of cell type-specific Stat3 threshold lev-
els required for neoplastic transformation, akin to those
described for the canonical Wnt pathway [97,98].
While epithelial Stat3 activity is dispensable during
normal development and tissue homeostasis of the adult
intestine, reduction of Stat3 expression, by either ablating
il6  [84] or depleting the capacity of gp130 to activate
Stat3, increases susceptibility to acute colitis and impairs
intestinal wound healing [30]. In humans STAT3 repre-
sents one of the disease loci for Crohn's and inflamma-
tory bowel disease (IBD) [99], and most likely relates to
the capacity of Stat3 to promote intestinal barrier func-
tion and integrity in response to IL6, IL11 and IL22 expo-
sure. Expression of IL22 during chronic inflammation
provides a directional signal from immune cells to epithe-
lium, as immune cells lack IL-22R (Figure 4). Sustained
activation of Stat3 in (intestinal) epithelium, brought
about by activation of the Socs3-unresponsive IL10R,
IL22R or gp130Y757F receptors, induces an anti-microbial
response. This comprises induction of mucins, lipocalin-
2, RegIIIβ, RegIIIγ, and β-defensins to buffer the epithe-
lium against an inappropriate innate immune response
elicited by commensal bacteria and to prevent gastroin-
testinal inflammation and colitis [100-102]. Accordingly,
experimental delivery of IL22 to mice with DSS-induced
colitis reduced inflammatory infiltrates and promoted
the mucosal healing response by goblet cells [103,104].
Thus, deficiency in Stat3, IL6 or IL11 signaling increases
the susceptibility to colonic mucositis in CAC-challenged
mice, but safeguards against excessive proliferation, sur-
vival and angiogenic activity of mutagenized cells. By
contrast, the very mechanisms that confer resistance to
colitis in Stat3 proficient epithelium also promote
tumourigenesis, including IL22-dependent induction of
tumour-promoting inducible nitric-oxide synthase [105].
Since Stat3 hyperactivation is frequently fueled by
excessive IL6, an important autocrine amplification loop
arises from the capacity of phosphorylated Stat3 to
induce its own transcription, where de novo Stat3 protein
in turn directly promotes expression of il6  without a
requirement for tyrosine phosphorylation (Figure 4)
[106]. The functional relevance of these autocrine and
paracrine feed-forward loops, originally proposed in
multiple myeloma [107] and comprising the IL6/gp130/
Stat3 cascade, has recently been extended to solid
tumours, including lung adenocarcinoma [20], prostate
cancer [108], ovarian carcinoma [109] and Ras-trans-
formed cancer cells [110]. In Ras-transformed cancer
cells, serine phosphorylated Stat3 may also aid tumour
growth by promoting metabolic functions in mitochon-
dria possibly through its association with Grim19 [111],
and stimulation of the electron transport chain in a tran-
scription independent way [112].
While there is ample evidence for IL6 in promoting
tumour activity on epithelium, the role played by the
other family members is less well defined. We have iden-
tified a prominent role for non-haematopoietic IL11
rather than (myeloid-derived) IL6 in promoting gastric
tumour formation in the gp130Y757F mouse model [32].
IL11 expression correlates with development of intesti-
nal-type gastric adenocarinoma in humans, and IL11Rα
expression is linked to cancer depth and venous vessel
invasion [113]. Since IL11 is expressed in epithelial and
stromal cells, and its gene is transcriptionally activated by
Stat3 [32], it remains to be established whether IL11 may
also provide an autocrine and paracrine feed forward
mechanism that, akin to IL6, fuels Stat3-dependent pro-
gression of tumours other than those of the stomach.
Stat3 in myeloid cells
Many of the inflammatory cytokines found in the tumour
microenvironment are derived from activated myeloid
cells, in particular neutrophils, DC, mast cells and mac-
rophages, where a tightly controlled Toll-like receptor
(TLR)-pathway regulates the innate immune response.
Excessive TLR signaling can promote tumourigenesis,
since ablation of the adaptor molecule MyD88 reduced
intestinal tumourigenesis in ApcMin;MyD88-/- compound
mutant mice [114]. Indeed, it has been speculated that
debris from dying neoplastic cells may elicit TLR-depen-
dent activation of macrophages or Kupfer cells in the liver
[115] and engage the transcription factor NF-κB pathway
through activation of its catalytic subunit IKKβ and cul-
minating in induction of TNFα, IL-1 and IL-6 [116].
Thus, systemic administration of an IKKβ-specific inhibi-
tor reduced Stat3 activation and IL6-target gene expres-
sion and ameliorated disease in colitis-prone IL10-
deficient mice [117]. Similarly, myeloid-specific ablation
of IKKβ inhibited tumour promotion and malignant cell
proliferation in tobacco smoke- or oncogenic K-Ras-
induced lung cancers [118], and reduced tumour size and
multiplicity in the colon of CAC-challenged mice
[11,119]. Indeed, high levels of IL6 in the tumour
microenvironment are associated with the progression of
colorectal [120], pancreatic [121], lung [122] and prostate
cancer [123]. Furthermore, the incidence of hepatocellu-
lar carcinoma in humans, or in DEN- and CAC-induced
tumours in mice, is less prominent in females due to the
capacity of estrogen to suppress IL6  transcription
[115,124]. The genetic ablation of il6 diminishes tumour
burden in ApcMin and in CAC-challenged wild-type miceJarnicki et al. Cell Division 2010, 5:14
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[84,125], DEN-induced liver [115] and in a tobacco
smoke-associated lung cancer model [118]. Although
gastric tumourigenesis in gp130Y757F mice occurred inde-
pendently of IL6 [32], we found that MyD88-deficiency
reduced their tumour burden (Jarnicki A, Puoczki T,
Ernst M: A mouse model for innate immune cell-medi-
ated gastric tumorigenesis, submitted), consistent with
our observation that excessive Stat3-activation increases
Tlr4  expression and susceptibility of these mice to
lipopolysaccharide-induced septic shock (Jenkins B, Jar-
nicki A, Thiem S, Ernst M: Systemic alteration of IL6-
mediated Stat3 signaling increases susceptibility to endo-
toxemia in mice, submitted).
Aberrant Stat3 activation in tumour cells promotes the
secretion of immunomodulatory factors, which selec-
tively reduce the Th1 dominated anti-tumour response
[126]. In response to tumour-derived IL10 and VEGF, for
instance, excessive Stat3 activity in myeloid cells inhibits
maturation and activation within the DC lineage, favours
polarization and activation of tumour associated mac-
rophages (TAM), and reduces cytotoxic activity of neu-
trophils and NK cells [127]. The physical contact between
tumour and antigen presenting cells also directly acti-
vates Stat3 and triggers a tolerogenic DC phenotype
[128]. The capacity of Stat3 to modulate the anti-tumour
immune response in macrophages and DCs partly
depends on the heterodimeric IL12 cytokine family,
which directs the outcome of inflammatory processes.
Activation of tissue macrophages and DCs, for instance,
results in production of IL12 (comprising IL12a/IL12b
heterodimers) and subsequent INFγ-dependent Th1 and
CTL anti-tumour responses. Meanwhile, IL10-mediated
sustained Stat3 activation in TAMs represses IL12
expression and promotes production of IL23 (comprising
IL23a/IL12b heterodimers), which helps to propagate the
Th17 T-cell subset [129]. These findings reiterate the crit-
ical role played by Socs3 in maintaining an inflammatory,
anti-tumourigenic environment characterized by IL12
expression that is converted to a tumour promoting
cytokine profile when Socs3 is unable to abate gp130 sig-
naling following engagement of the IL10 family receptor
components. Accordingly, administration of Stat3 antag-
onists reduces tumour burden even in xenograph models
where the primary tumour is not sensitive to inhibition of
Stat3, suggesting that Stat3 inhibition provides a benefi-
cial "bystander" effect on tumour cell killing that is asso-
ciated with extensive tumour-specific lymphocyte
infiltration [130]. Furthermore, Stat3-deficient myeloid
derived suppressor cells fail to promote the formation of
vessel-like structures in vitro, because induction of the
pro-angiogenic factors VEGF, bFGF, IL-1β, MMP9, CCL2
and CXCL2 is Stat3 dependent [74]. Although, these
observations suggest that excessive Stat3 activation
within the myeloid cell lineages indirectly enhances
tumour progression by subverting anti-tumour immu-
nity, the contribution of myeloid Stat3 activation to the
growth of tumours that are driven by persistent epithelial
Stat3 activation remains less well understood. Systemic
Stat3 inhibition, for instance, reduced gastric tumour
burden even in gp130Y757F mice that had undergone adop-
tive bone marrow transfer with wild-type cells [32].
Stat3 in lymphoid cells
The Th17 subset of T-cells secrete large amounts of
IL17A, which induces the angiogenic factors VEGF and
TGFβ in fibroblasts and endothelial cells [131], and both
IL17 and IL23 promote tumourigenesis [132,133]. Stat3 is
indispensible for the development of the Th17 cell lin-
eage, as it enables expression of the transcription factor
RoRγt, which facilitates IL6-mediated polarization of
naïve CD4 cells, and transcriptionally induces the IL-17a
gene [134]. Thus, excessive Stat3 activity enforces differ-
entiation into Th17 cells even in the context of Th1 polar-
ising anti-tumour conditions [135], and genetic
interference with the IL6/gp130 pathway selectively
blocks Th17 cell polarization [136]. Although polariza-
tion of naïve CD4 to Th17 as well as Treg cells requires
tumour-associated TGFβ in mice, only Th17 differentia-
tion requires Stat3 activity. Accordingly, the extent of
lymphocytic Stat3 activation directly shapes the overall
tumour immune response including the Treg's capacity to
deprive Th17 cells from essential activation cues [137].
Importantly, IL17 and IL23 alongside IL22 and cell-
autonomous acting IL21, all promote and stabilize the
Th17 phenotype and sustain inflammation [138] through
various Stat3-dependent feed-forward loops within the
tumour, stromal and haematopoietic cells of the microen-
vironment [133] (Figure 4). The existence of these net-
works are corroborated by findings that exposure of pre-
neoplastic epithelium of ApcMin mice to the enterotoxic
Bacteroides fragilis promotes colon tumourigenesis
through an IL17-/Stat3-dependent mechanism [139].
Although  H.pylori-associated gastritis coincides with a
marked mucosal induction of IL17 and IL23 [140], and
these cytokines are also elevated in gastric cancer bearing
gp130Y757F mice (Putoczki T, Ernst M: A role for IL17 in a
mouse model of gastric cancer, submitted), the latter
tumours also develop in gp130Y757F;Rag-/-  mice in the
absence of adaptive immune cells [141]. Indeed, the
gp130-family cytokine IL-27 may promote an anti-
tumour response by suppressing Th17 cell polarization
and favouring Th1 differentiation through its capacity to
activate Stat1 [142].
Crosstalk of Stat3 with NF-κB and Wnt/β-catenin pathways
While Stat3 provides a major molecular link between the
inflammatory response and epithelial tumourigenesis,
some of its functions are also shared with NF-κB. LikeJarnicki et al. Cell Division 2010, 5:14
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Stat3, canonical activation of NF-κB induces genes that
encode anti-apoptotic functions (incl. Bcl-XL, Gadd45b,
Bfl1,  Sod2, etc. [11,119]) to facilitate survival of (neo-
plastic) cells. Therefore, inhibition of canonical NF-κB
activating through ablation of the IKKβ gene in the intes-
tinal epithelium decreased tumour incidence (but not
size) in the colon of CAC-challenged mice [11,119]. Epi-
thelial NF-κB activation results from the rich abundance
of IL1β, TNFα and TLR-agonists in the tumour microen-
vironment, and IL1β, TNFα and many other cytokines
and chemokines (i.e. IL6, CXCL2, CCL2 and CCL20) are
transcriptional targets for NF-κB [119,143]. The intimate
link between inflammation-associated hyper-activation
of NF-κB and Stat3 has recently been extended by a fur-
ther feed-forward loop, whereby NF-κB induction of the
RNA binding protein Lin28 blocks processing of the let-7
microRNA (Figure 4) and thereby de-represses transcrip-
tion of il6 [144]. It also has been suggested that Stat3 sig-
naling prolongs nuclear retention of canonically activated
NF-κB through RelA/p50 acetylation and associated
interference with its nuclear export [145]. Importantly
NF-κB and Stat3-mediated signaling converge on the
EMT process where IL6-mediated Stat3 activation pro-
motes EMT through transcriptional induction of the E-
cadherin repressor snail [146], while activation of NF-κB
promotes posttranslational stabilization of the Snail pro-
tein [147]. Unphosphorylated Stat3 can also cooperate
with the NF-κB pathway by competing with IKKβ for
binding to unphosphorylated NF-κB, and this complex
activates genes, such as rantes and il8, independent of
their binding sites for NF-κB and/or Stat3 [148].
While NF-κB and Stat3 cooperatively enhance survival
of (neo)plastic cells through transcription of shared sur-
vival genes, the molecular mechanisms underlying func-
tional cooperation between the aberrantly activated Stat3
and Wnt/β-catenin pathways are less clear. Evidence for
the latter comes from the observation that all colonic
tumours in the CAC-challenged gp130Y757F mice harbour
activating mutations in β-catenin, and that
gp130Y757F;ApcMin mice show increased tumour multiplic-
ity [68,93], while enterocyte-specific Stat3 ablation
reduced tumour incidence in ApcMin mice [33]. Although
the two pathways share transcriptional responsiveness of
proliferative target genes, such as c-myc  and  cyclinD1,
IL11 administration and excessive Stat3 activation also
facilitates survival of epithelial cells with the capacity to
repopulate the intestine after radiation damage [92]
(Phesse T, Buchert M, Ernst M: Epistatic interaction
between aberrant Wnt and Stat3 signaling during intesti-
nal tumorigenesis, submitted). Similarly, Stat3 promotes
survival of tissue stem cells and suppresses their differen-
tiation [144,149] in mutagen challenged skin models and
in mouse embryonic stem (ES) cells. In the fruitfly, the
genes dome, hop and Stat92E (orthologues of mammalian
gp130, Jak and Stat3, respectively) are required to rein-
state gut homeostasis following apoptosis, enteric infec-
tion, or c-jun kinase (JNK)-mediated stress signaling
[150]. In mammals the gene encoding intestinal Krüppel-
like factor (Iklf/Klf5) is a target for gp130-signalling, pro-
motes ES cell pluripotency [151] and mediates epithelial
hyperplasia in the intestine [152]. Stat3 may therefore
increase the pool of "stem" cells susceptible to tumour-
inducing mutation, including loss-of-heterozygosity in
ApcMin mice. Moreover, the failure to eliminate cyclin D1
in situations of sustained Stat3 activation may not only
bypass the DNA replication checkpoint response [153],
but also facilitate aberrant chromosome segregation trig-
gered in the absence of functional Apc protein [154].
Targeting Stat3 activity
The preclinical observations cited above suggest that the
growth and maintenance of many tumours, including
some that are not caused by aberrant activation of Stat3,
have become addicted to its continuous activation. How-
ever, systemic deletion of Stat3 is incompatible with
embryonic development, and tissue-specific Stat3 abla-
tion in adult mice triggers enterocolitis, impairs T-cell
migration and ultimately causes Th1 autoimmunity [155].
Similarly, a dominant-negative mutation in STAT3
reduces its activity in human CD4 cells by approximately
75% and is associated with Hyper-IgE syndrome [156].
The latter finding is consistent with genetic observations
obtained in compound mutant mice where reduction of
Stat3 by more than 50% of its activity results in patholog-
ical outcomes [157]. However, systemic Stat3 haploinsuf-
ficiency suppresses growth of gastrointestinal tumours,
without interfering with physiological responses during
a d u l t,  f e c u n d  l i f e  [ 3 2 , 3 3 ] .  T h e s e  o b s e rv a t i o n s  r a i s e  t h e
exciting prospect for a therapeutic window, in which par-
tial interference with Stat3 signaling may selectively affect
tumours without the need to specifically target tumour
(or tumour-associated immune) cells.
Soluble ligands have been extensively targeted by anti-
body-mediated therapies, and antibodies directed against
IL6 and IL6Rα show promising results in the treatment of
rheumatoid arthritis and other chronic inflammatory dis-
eases. However, due to extensive redundancy among
cytokines that activate Stat3, direct inhibition of Stat3
(activity) may show additional therapeutic benefits. Tra-
ditionally, pharmaceutical efforts have concentrated on
targeting tyrosine kinases, and several inhibitors with
specificity against Stat3-activating kinases, including EGF
receptor, c-src, and Jak2, are either already in the clinic or
undergoing preclinical testing [158]. These approaches
are likely to be complemented by future developments of
drugs that inhibit Stat3 directly. Indeed, a number of nat-
ural compounds and their derivatives, including cur-
cumin, curcubitacins, resveratrol as well as indirubin andJarnicki et al. Cell Division 2010, 5:14
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platinum complexes, have been shown to interfere with
Stat3 activity. Their inhibitory activity most likely arises
from a combination of binding directly to Stat3 as well as
interfering with other cellular processes, and although
compounds such as STA-21, S31-M2001 or S3I-201 sup-
press the growth of breast cancer, myeloma and mela-
noma cell lines in xenograph model, the clinical utility of
these molecules still awaits confirmation. Other
approaches include peptidometics and small molecules
that target Stat3 dimerization, double-stranded decoy oli-
gonucleotide to compete with Stat3 binding to target
genes [159,160], as well as suppression of transcription
and translation through the development of antisense-
oligonuclotides [32] and small inhibitory RNA [161].
As we learn more about the underlying changes result-
ing from aberrant activation of Stat3, we will gain better
insights into which of the aforementioned approaches
may be most suitable to a particular situation. It is worth-
while to consider whether Stat3-driven tumours also
develop addictions to non-oncogene pathways that are
amenable to therapeutic interference [162]. Simultaneous
targeting of such pathways in tumour cells, perhaps in
conjunction with antibody-based strategies to curb
cytokine-mediated activation of Stat3 (and NF-κB) in
immune cells may hold therapeutic potential.
Conclusions
While a link between inflammation and cancer has been
known for more than a century, we now start to unravel
underlying mechanisms by which chronic inflammation
promotes many human cancers. Compelling recent evi-
dence suggests that Stat3, alongside with NF-κB, acts as
the signaling node which provide the functional link by
which aberrant activation of inflammatory cells within
the tumor microenvironment triggers an epithelial sur-
vival and growth response that promotes overgrowth of
neoplastic cells. The skewed anti-inflammatory gene
response elicited by prolonged Stat3 activation in myeloid
cells, on the other hand, curbs the immune system's anti-
tumour response, while excessive Stat3 activation in
inflammatory Th17 T-cells further fuels tumour growth
and angiogenesis. Persistent activation of STAT3, most
prominently observed in the epithelial and immune cells
that constitute the tumour invasive front, often results
from autocrine and paracrine production of IL6-family
cytokines by the tumour and associated stroma [143]. IL6
provides an important link between obesity, aging,
chronic inflammation and cancer [163], and a wealth of
genetic models now permits detailed dissection of the
contribution of individual signaling components within
specific cell types. A comprehensive understanding of the
gp130/Stat3 signaling cascade holds great promise to
identify and validate therapeutic targets that simultane-
ously restrict the effect of tumour promoting inflamma-
tion while restoring anti-tumour immunity.
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